









Markets
/
Stocks
/
nasdaq-ug
/

United-Guardian Inc

7.150USD

0.0000.00%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

32.85MMarket Cap

16.76P/E TTM



United-Guardian Inc

7.150

0.0000.00%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of United-Guardian Inc

Currency: USD Updated: 2026-02-06

Key Insights

United-Guardian Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 104 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

United-Guardian Inc's Score

Industry at a Glance

Industry Ranking

104 / 159

Overall Ranking

297 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

United-Guardian Inc Highlights

StrengthsRisks

United-Guardian, Inc. is a manufacturer of cosmetic ingredients, sexual wellness ingredients, pharmaceuticals, and medical lubricants. The Company’s product lines include the Lubrajel line of multifunctional hydrogel formulations, which are designed to provide sensory enhancement, lubrication, hydration, and texture to both personal care and medical products. Its four distinct product categories include cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. Its COSMOS line of products includes Lubrajel Natural, Lubrajel Marine, Lubrajel Oil Natural, and Lubrajel Terra. Its medical lubricants include a line of hydrogel formulations designed to offer sensory enhancement and lubrication to medical products. The Company’s pharmaceutical products include an FDA-approved prescription drug that is used primarily to prevent and to dissolve calcifications in urethral catheters, as well as a chlorine-based topical antimicrobial.

Growing

The company is in a growing phase, with the latest annual income totaling USD 12.18M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 12.18M.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 84.79%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 84.79%.

Overvalued

The company’s latest PE is 16.76, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.03M shares, decreasing 6.64% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 184.76K shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of United-Guardian Inc is 9.42, ranking 3 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 2.26M, representing a year-over-year decrease of 26.01%, while its net profit experienced a year-over-year decrease of 68.98%.

Score

Industry at a Glance

Previous score

9.42

Change



Financials

8.86

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

8.24

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

United-Guardian Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of United-Guardian Inc is 7.83, ranking 46 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 16.76, which is 33.01% below the recent high of 22.29 and 37.10% above the recent low of 10.54.

Score

Industry at a Glance

Previous score

7.83

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 104/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for United-Guardian Inc. The Pharmaceuticals industry's average is 7.85.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of United-Guardian Inc is 8.56, ranking 51 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 7.85 and the support level at 6.31, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.59

Change

-0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.092

Buy

RSI(14)

61.987

Neutral

STOCH(KDJ)(9,3,3)

65.795

Neutral

ATR(14)

0.307

Low Volatility

CCI(14)

51.098

Neutral

Williams %R

37.931

Buy

TRIX(12,20)

0.696

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

7.314

Sell

MA10

7.076

Buy

MA20

6.749

Buy

MA50

6.314

Buy

MA100

6.754

Buy

MA200

7.512

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of United-Guardian Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 22.38%, representing a quarter-over-quarter decrease of 2.23%. The largest institutional shareholder is James Simons, holding a total of 184.76K shares, representing 4.02% of shares outstanding, with 2.22% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Globus (Kenneth H)

1.32M

Parker (Betsee)

310.59K

-7.87%

Gabelli Funds, LLC

197.50K

Renaissance Technologies LLC

Star Investors

184.76K

-1.70%

The Vanguard Group, Inc.

Star Investors

150.40K

Monongahela Capital Management

82.27K

-8.36%

Dimensional Fund Advisors, L.P.

77.53K

+0.79%

Teton Advisors, Inc.

53.96K

-0.37%

Teton Advisors, LLC

53.96K

Parthenon LLC

50.91K

-1.93%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of United-Guardian Inc is 4.12, ranking 94 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.00. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.